3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotech names with improving commercial and clinical catalysts: Madrigal reported Q1 revenue up 127% year over year to $311.3 million with over 42,250 Rezdiffra patients treated, Axsome grew Q1 revenue 57% to $191.2 million and secured an Auvelity label expansion for Alzheimer’s agitation, and Kailera is advancing multiple obesity pipeline assets. The most concrete near-term catalyst is Axsome’s new indication, while Madrigal continues to scale its first approved MASH drug. Overall tone is constructive but speculative, with the focus on long-term upside from clinical and regulatory progress.

Analysis

MDGL and AXSM are not just “good biotech stories”; they are becoming commercial execution stories, which matters because the market typically rerates these names only when penetration inflects from specialist enthusiasm to repeatable prescribing. The key second-order effect is competitive response: once a category proves it can generate meaningful revenue, larger pharmas with broader commercial infrastructure will tend to enter, compressing long-duration monopolistic assumptions and shifting the edge toward companies that can expand label breadth faster than competitors can match. In that sense, the durability of the revenue slope over the next 12-24 months matters more than the absolute growth rate cited today.

For MDGL, the base case is stronger than the headline suggests because first-mover advantage in a specialist-diagnosed disease creates a sticky referral loop, but the stock is also vulnerable to any signal that breadth of adoption is slowing before the addressable specialist pool is meaningfully penetrated. The hidden risk is not just competition from other approved therapies; it is payor step-editing and prescriber fatigue if the therapeutic class becomes crowded faster than outcomes differentiation is proven. That makes the next 2-3 quarters a commercial-trend trade, not a long-dated MASH thesis.

AXSM has the more interesting asymmetry because the new indication expands the total prescriber universe and gives management multiple shots on goal, which can keep multiple expansion alive even if one launch underwhelms. The contrarian issue is that investors may be overestimating how quickly a broad neurology/psychiatry sales force can convert label expansion into sustained revenue per rep; if uptake is slower than expected, the market could de-rate the name despite still-strong top-line growth. This sets up a favorable setup for owning dips only after launch data confirms refill behavior and payer access rather than buying ahead of the initial enthusiasm spike.

Key Decisions for Investors

• Overweight MDGL on pullbacks over the next 1-2 quarters, but size it as a commercial-execution long rather than a platform compounder; upside is attractive if specialist penetration keeps compounding, but cut risk quickly if quarterly uptake or access metrics decelerate.
• Stay long AXSM into the next 2 earnings prints; the setup favors a positive revision cycle if the new label begins to move reimbursement and script velocity, with better risk/reward than MDGL because multiple growth drivers reduce single-asset dependence.
• Use KLRA only as a small, event-driven position into phase 3/oral-development catalysts; treat it as high convexity with binary downside, and avoid holding oversized exposure through financing windows.
• Pair trade idea: long AXSM / short NVO on a relative basis for 3-6 months if you believe smaller-cap launch execution will surprise to the upside while large-cap obesity expectations are already crowded; the spread should work if innovation breadth, not size, drives near-term re-rating.
• Sell upside calls against any existing MDGL long into sharp post-news strength; competition risk makes outright multiple expansion vulnerable once the market prices in broader MASH field congestion.